Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.50 |
| ▸ | CALCR | P30988 | 7/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455187 | 0.95 | RAMP3 (0.50) | OPRM1OPRK1CXCR4RAMP3CALCR | |
| SCHEMBL29904044 | 0.90 | OPRM1 (0.55) | OPRM1OPRK1CXCR4RAMP3CALCR | |
| SCHEMBL38655507 | 0.90 | OPRM1 (0.55) | OPRM1OPRK1CXCR4RAMP3CALCR | |
| SCHEMBL31232470 | 0.89 | RAMP3 (0.58) | OPRM1OPRK1CXCR4RAMP3CALCR | |
| SCHEMBL30937368 | 0.87 | RAMP3 (0.44) | CXCR4RAMP3CALCRNTSR2NTSR1 | |
| SCHEMBL30175378 | 0.87 | RAMP3 (0.56) | CXCR4RAMP3CALCR | |
| SCHEMBL30039196 | 0.86 | RAMP3 (0.56) | OPRM1OPRK1CXCR4RAMP3CALCR | |
| SCHEMBL29914692 | 0.86 | OPRM1 (0.50) | OPRM1OPRK1CXCR4APLNRNTSR2 | |
| SCHEMBL29736175 | 0.86 | RAMP3 (0.58) | CXCR4RAMP3CALCR | |
| SCHEMBL6158368 | 0.86 | RAMP3 (0.51) | OPRM1OPRK1CXCR4RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3129357-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | AF Chemicals, LLC, (US) | 2023-07-06 | — | — | US | disclosed |
| US-11591295-B2 | Affinity illudofulvene conjugates | AF CHEMICALS LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | OPRM1 724/4885OPRK1 564/4885CXCR4 1141/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | OPRM1 1990/4885OPRK1 1303/4885CXCR4 833/4885 |
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | OPRM1 724/4885OPRK1 564/4885CXCR4 1141/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | OPRM1 1990/4885OPRK1 1303/4885CXCR4 833/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | OPRM1 1990/4885OPRK1 1303/4885CXCR4 833/4885 |
| US-11591295-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | OPRM1 724/4885OPRK1 564/4885CXCR4 1141/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | OPRM1 724/4885OPRK1 564/4885CXCR4 1141/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | OPRM1 1990/4885OPRK1 1303/4885CXCR4 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.